TNB-585

N/A

Report date: 2026/03/19 17:22:33

Base Information

Drug NameTNB-585
Drug Alias NameAnti-PSMAxCD3CD3xPSMA Bispecific AntibodyCD3xPSMA T-BsAbTNB-585AMG-340
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-PSMA
TargetsT cell surface glycoprotein CD3Prostate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTeneobio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTeneobio Inc
Inactive CompaniesAmgen Inc
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A